Article content

A Canadian company is developing a cannabis-centric solution for Cutaneous T-cell lymphoma (CTCL), an uncommon type of cancer occurring in adults aged 40 to 60 and sometimes in children.

We apologize, but this video has failed to load.

tap here to see other videos from our team. Try refreshing your browser, or Canadian company developing a cannabis cure for a rare type of skin cancer Back to video

“One study estimated that from 0.5 to five percent of all CTCLs occur in children,” as reported by National Organization of Rare Disorders. Causing the skin to develop small, pimple-looking lumps that can be felt or open sores, red patches, CTCL could even result in life-threatening complications.

MedC Biopharma Ltd., a Canadian manufacturer of cannabis-based medicines, is developing a cannabis centric solution for this very problem.

Founded in 2016 by Avi Drori, president and chairperson, and Guy Drori, CEO, MedC Biopharma Ltd.’s products are focused on post-traumatic stress disorder (PTSD), psoriasis and CTCL. The company has also signed an exclusive licensing agreement with National Medical Cannabis Research Lab at Agricultural Research Organization (ARO)—the Volcani Center, Israel.